RxDoctor Payments Data

Briana Weidler-Edholm, NP

Nurse Practitioner · South Bend, INNPI 1144882069

Payments from drug & device makers

$1,855in general payments, 2019–2025

Across 97 payments — averaging $19.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$288
  • Novartis$272
  • AbbVie$248
  • Pfizer$220
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$183
  • AstraZeneca$104
  • plus $540 from 16 others

What the payments were for

  • Food & beverage$1,75194%
  • Education$1046%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,855 in reported general payments places this provider in the 80th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Medicare billing

Part B allowed, 2024
$40,361
Medicare patients
231
Services billed
386

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase63$188,730
EliquisApixaban63$73,168
LinzessLinaclotide45$31,282
MotegrityPrucalopride Succinate15$9,055
Dexlansoprazole DrDexlansoprazole20$3,881
Lubiprostone28$2,597
Omeprazole103$1,031
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates16$960
Metoprolol Succinate69$588
Pantoprazole Sodium82$554
Ondansetron OdtOndansetron12$530
Spironolactone39$475
Famotidine49$355
Dicyclomine Hcl16$340
Atorvastatin Calcium44$292

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$248$220,011108 claims
PfizerEliquis$220$73,16863 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$55$9,05515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in South Bend

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →